ArticleAbdominal radiology (New York)2026
Multimodal prediction of metachronous liver metastasis in stage I-III colorectal cancer patients: multicenter cohort study employing machine learning.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivePostoperative metachronous liver metastasis (MLM) in colorectal cancer (CRC) patients is often difficult to predict using conventional clinical and radiological methods, which may result in delayed diagnosis and treatment. We aimed to develop and validate an artificial intelligence integrated model to improve MLM prediction after CRC surgery.
methodsA retrospective study was analyzed (n = 522) CRC patients underwent for radical surgery between 2014 and 2019. Categorized into MLM (n = 106) and non-MLM (n = 416) groups based on the presence of postoperative liver metastasis within 5 years. The dataset was split 8:2 for training and validation, utilizing 5-fold cross-validation. Data included demographic factors, tumor characteristics, laboratory results, and CT arterial-phase images. Feature selection employed Random Forest Boruta and Lasso Regression with 5-fold cross-validation to identify key predictors. A Multimodal model integrated numerical and image data (CMLM) was developed, integrating value-based features through a Self-Attention Dense ResNet (SAD) module and image-based features through a Convolution Vision Transformer (CVT) module. Features extracted from SAD and CVT were fused by feature splicing, and MLM was predicted by full connection layer. Model performance was assessed by ROC curves, calibration curves, decision curves, and survival analyses. Interpretability was enhanced through Shapley values for numerical data and Grad-CAM for imaging data.
resultsThe fusion model CMLM predicts the accuracy of MLM at 0.88 (0.84-0.91), with a recall rate of 0.80 (0.75-0.84), an F1 score of 0.78 (0.75-0.81), and an AUC value of 0.85 (0.84-0.86), which is higher than the accuracy, recall rate, F1 score, and AUC values of the single-modality models SAD the performance metrics for the model are as follows: an accuracy rate of 0.71 (0.56-0.86), a recall rate of 0.60 (0.53-0.68), an F1 score of 0.55 (0.45-0.65), and the AUC value of 0.69 (0.68-0.69). In comparison, the CVT model exhibits an accuracy rate of 0.66 (0.50-0.83), recall rate of 0.65 (0.63-0.67), F1 score of 0.57 (0.49-0.65), and the AUC value of 0.72 (0.70-0.73), with a statistically significant difference (p < 0.001). The top five key predictive factors for SAD included ANC, ALB, ALC, pT stage, and PNI. Grad-CAM highlighted key regions for predicting MLM in imaging information of the preoperative primary lesions, showing similar results in independent external data validation, exhibits robust generalization.
conclusionThe model that integrates clinical modalities and primary tumor lesion modalities can significantly improve the prediction of MLM after CRC surgery, providing a valuable tool for early detection, diagnosis, and treatment.
Indexed as
Identifiers
42474718What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.